Title : JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.

Pub. Date : 2017 Apr

PMID : 27812788






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The SF2/ASF reduction, parallel to JCV activation, during the second year of therapy with natalizumab, but not with fingolimod, may help explain the increased risk of PML after the second year of treatment with natalizumab, but not with fingolimod. Fingolimod Hydrochloride serine and arginine rich splicing factor 1 Homo sapiens
2 The SF2/ASF reduction, parallel to JCV activation, during the second year of therapy with natalizumab, but not with fingolimod, may help explain the increased risk of PML after the second year of treatment with natalizumab, but not with fingolimod. Fingolimod Hydrochloride serine and arginine rich splicing factor 1 Homo sapiens